Hikma Pharmaceuticals Plc, a pharmaceutical company based in the United Kingdom, specializes in developing, manufacturing, and marketing a wide range of generic and branded pharmaceutical products. With a medium risk assessment ESG score of 23.7, the company operates in three segments: injectables, generics, and branded. Its primary revenue comes from supplying hospitals with generic injectable products in North America, followed by markets in the Middle East, North Africa, Europe, United Kingdom, and globally.